UBS Group
CTKB icon

UBS Group’s Cytek Biosciences CTKB Stock Holding History

UBS Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$394K Sell
88,914
-97,967
-52% -$418K ﹤0.01% 6387
2026
Q1 		$817K Sell
186,881
-273,166
-59% -$1.29M ﹤0.01% 5707
2025
Q4 		$2.32M Sell
460,047
-8,642
-2% -$40.1K ﹤0.01% 4831
2025
Q3 		$1.63M Sell
468,689
-163,363
-26% -$613K ﹤0.01% 5156
2025
Q2 		$2.15M Buy
632,052
+20,524
+3% +$68.4K ﹤0.01% 4748
2025
Q1 		$2.45M Sell
611,528
-54,205
-8% -$281K ﹤0.01% 4530
2024
Q4 		$4.32M Buy
665,733
+646,789
+3,414% +$3.85M ﹤0.01% 3986
2024
Q3 		$105K Sell
18,944
-60,588
-76% -$344K ﹤0.01% 6319
2024
Q2 		$444K Sell
79,532
-3,375
-4% -$20.3K ﹤0.01% 5088
2024
Q1 		$556K Buy
82,907
+82,885
+376,750% +$656K ﹤0.01% 5113
2023
Q4 		$201 Sell
22
-595
-96% -$3.75K ﹤0.01% 8813
2023
Q3 		$3.41K Sell
617
-231,992
-100% -$1.86M ﹤0.01% 7562
2023
Q2 		$1.99M Buy
232,609
+155,295
+201% +$1.39M ﹤0.01% 3533
2023
Q1 		$711K Buy
77,314
+32,198
+71% +$346K ﹤0.01% 4407
2022
Q4 		$461K Buy
45,116
+41,103
+1,024% +$552K ﹤0.01% 4775
2022
Q3 		$59K Buy
4,013
+3,950
+6,270% +$51.3K ﹤0.01% 6175
2022
Q2 		$1K Buy
+63
New +$627 ﹤0.01% 9840
2021
Q4 		– Sell
-831
Closed -$18K – 10316
2021
Q3 		$18K Buy
+831
New +$19.5K ﹤0.01% 7270

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group's CTKB Position: Q2 2026 in Review

UBS Group reduced its Cytek Biosciences (CTKB) stake by 52% in Q2 2026, selling an estimated $418K and leaving 88,914 shares worth $394K. The position accounts for ﹤0.01% of the portfolio, ranked #6387.

UBS Group first reported a position in CTKB in Q3 2021 and has held it in 18 quarters since. The position peaked at $4.32M in Q4 2024. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • UBS Group held 88,914 shares of Cytek Biosciences worth $394K as of Q2 2026.
  • UBS Group sold 97,967 Cytek Biosciences shares in Q2 2026, an estimated $418K.
  • Cytek Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6387 holding.
  • UBS Group first reported a position in Cytek Biosciences in Q3 2021 and has held it in 18 quarters since.
  • UBS Group's Cytek Biosciences position peaked at $4.32M in Q4 2024.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.